Securities code: Berry Genomics Co.Ltd(000710) securities abbreviation: Berry Genomics Co.Ltd(000710) Announcement No.: 2022023 Berry Genomics Co.Ltd(000710)
Announcement on 2021 profit distribution plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 2021 profit distribution plan
Berry Genomics Co.Ltd(000710) (hereinafter referred to as "the company") according to the standard unqualified audit report of 2021 issued by Shanghai accounting firm (special general partnership): the company's profit available for distribution to shareholders at the end of 2020 was 105285896548 yuan, the net profit attributable to the parent company in 2021 was -11081856280 yuan, and the net profit available for distribution to shareholders as of December 31, 2021 was 94204040268 yuan.
The company's profit distribution plan for 2021 is: no cash dividend, no bonus shares, and no conversion of capital reserve into share capital in 2021.
2、 No profit distribution in 2021
According to the notice on further implementing matters related to cash dividends of listed companies issued by the China Securities Regulatory Commission, the guidelines for the supervision of listed companies No. 3 - cash dividends of listed companies and other relevant provisions of the articles of association, and in combination with the company's future business development plan, the company expects to expand the company's upstream and downstream business lines by means of investment in the next 12 months, Continue to improve the internal management structure of the company (the company will timely submit relevant matters to the board of directors or the general meeting of shareholders for deliberation according to the importance level of relevant matters).
3、 Deliberation of the board of directors
The profit distribution plan for 2021 was deliberated and adopted at the 16th meeting of the ninth board of directors of the company.
The board of Directors believes that the profit distribution plan for 2021 is made based on the company's current operating and financial conditions and in combination with the company's development plan for 2021. It does not violate relevant laws and regulations and the articles of association. No profit distribution in 2021 will provide financial support for the company's main business development, facilitate the company's business expansion, strengthen internal management and enhance the company's competitiveness, Better safeguard the long-term interests of all shareholders.
4、 Opinions of independent directors
After careful deliberation, the independent directors believe that the company's profit distribution plan for 2021 is formulated on the basis of comprehensively considering the future development plan, the company's profitability and cash flow. The voting procedure of the board of directors of the company on this proposal is open and transparent, the deliberation procedure is in line with the relevant provisions of laws, regulations and the articles of association, and there is no damage to the interests of minority shareholders.
5、 Opinions of the board of supervisors
After careful deliberation, the board of supervisors considered that the company's profit distribution plan for 2021 was in line with the current actual situation and future development plan, the deliberation and voting procedures of the board of directors on the company's profit distribution plan for 2021 were in line with relevant regulations, and there was no damage to the interests of the company's shareholders, and agreed with the company's profit distribution plan for 2021 The above profit distribution plan needs to be submitted to the 2021 annual general meeting for deliberation.
It is hereby announced.
Berry Genomics Co.Ltd(000710) board of directors April 14, 2022
